Department of Internal Medicine, The University of Arizona Medical Center, PO Box 245040, 1501 N Campbell Avenue, Tucson, AZ 85724, USA.
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):507-17. doi: 10.1586/egh.12.23.
To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.
为了降低结直肠癌（CRC）的发病率和死亡率，目前的临床实践侧重于筛查以早期发现和息肉切除术作为二级预防手段，并在适当情况下辅以手术干预。目前尚无药物制剂被批准用于 CRC 风险患者的临床管理。本文将回顾早期开发用于管理散发性或遗传性 CRC 风险患者的药物制剂的尝试。它还将讨论目前开发治疗 CRC 风险因素药物的努力中正在评估的治疗终点。
